###### Key questions

What is already known?
======================

-   Little is known about mark-ups and other add-on costs that contribute to the prices of medicines particularly in low/middle-income countries, and information available about other medicines may not be relevant to insulin, a biological product.

-   Recent insulin price surveys under the Addressing the Challenges and Constraints of Insulin Sources and Supply study found that insulin prices can be very high, depending on the type, presentation and brand of insulin.

What are the new findings?
==========================

-   Case studies of insulin price components, conducted in six low/middle-income countries, identified no systematic differences when comparing manufacturers, sectors, regions within the country, originator versus biosimilar products, human versus analogue insulin, or vials, cartridge or pens.

-   Price regulation led to less variability in mark-ups, but not necessarily lower prices, while import charges are still applied in some countries and value-added taxes are commonplace.

What do the new findings imply?
===============================

-   While there is no clear uniform approach to regulating price components of insulin in order to increase access and affordability, the removal of tariffs and taxes would be beneficial and wider price regulation can be useful where resources for implementation, enforcement and price monitoring exist.

-   Improved price transparency of insulin products will address information asymmetry in the market which affects patients and purchasers of healthcare.

Introduction {#s1}
============

Insulin is a life-saving medicine, yet access to it is poor especially in low/middle-income countries (LMIC). High prices are a key barrier for people needing insulin,[@R1] particularly low wage earners.[@R2] Insulin public procurement prices are high, have not fallen over time as with other medicines and some countries pay much higher prices than others.[@R1] A survey across 43 countries in 2015 found that patient prices for human insulins were much lower than for analogues in both the public (median US\$7.64 vs US\$45.03 for 10 mL 100 IU/mL) and private sectors (median \$16.65 vs \$39.35) with vials cheaper than pens and cartridges, but prices varied considerably between countries.[@R2] Low-wage workers would need about 3--10 days' wages to be able to purchase 10 mL of various insulin products. A more recent survey[@R3] in 2016 in 13 LMICs found that government procurement prices of the same insulin product could vary substantially (\$1.45 in Ethiopia vs \$24.72 in China for human isophane insulin), even when exactly the same brand (Lantus pen \$21.56 in Indonesia vs \$106.52 in China).

Studies in LMICs have found that government procurement policies, duties, taxes and supply chain issues are important barriers to insulin access.[@R4] Understanding the components that make up the final price (including the manufacturer's selling price (MSP), wholesale and retail mark-ups, tariffs, taxes and other charges) may help identify means of improving efficiency and reducing prices within the supply system.

Health Action International (HAI) and the WHO have developed a standard methodology for examining price components through the use of case studies.[@R6] Data from such studies for various medicines in LMICs show cumulative mark-ups between 11% and 6894%[@R7] and have led to policy changes, such as a move to regressive mark-ups in Lebanon.[@R9] However, price components specifically of insulin have not been studied and no other data are available. This paper presents a series of country case studies investigating insulin price components in selected LMICs as part of the Addressing the Challenges and Constraints of Insulin Sources and Supply (ACCISS) study in order to inform policy recommendations.

Methods {#s2}
=======

The WHO/HAI methodology[@R6] was adapted to only look at insulin products as described below. Six countries were purposively selected which had recently undertaken an insulin price and availability survey as part of the ACCISS study: Brazil (Rio de Janeiro Province), China (Hubei and Shaanxi Provinces), Ghana, India (Haryana State), Indonesia and Uganda.

The countries have varied health systems and approaches to insulin supply and pricing particularly in the public sector. In Brazil, human insulins are produced locally and are provided free in the public sector. However, imported analogue insulins may also be supplied and charged for. China caps public procurement prices and has recently instituted a zero mark-up policy for the public sector to replace a previous 15% mark-up. Patients may have to pay for insulin depending on their level of insurance and where they obtain their supply. There are local producers of biosimilar analogue insulins. In Ghana, all insulin is imported and public sector retail prices are set by the national health insurance (NHI) system. India has multiple producers of human and biosimilar insulin. Insulin specified on the national essential medicine list should be free in the public sector. Indonesia has universal NHI which sets procurement prices and distribution margins for insulins, which are all imported. Insulin is fully reimbursed under the health insurance. Uganda imports all insulin products which are provided free in the public sector. A brief summary of pharmaceutical policies in each country relevant to insulin is presented in online [supplementary file 1](#SP1){ref-type="supplementary-material"}.
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Product and facility selection {#s2-1}
------------------------------

From the price and availability survey data,[@R3] at least five insulin products were purposively selected based on availability, type (human, analogue and animal insulin), manufacturer and presentation. Thus, the survey included the most common products but also attempted to capture examples of analogue insulins and both vials and cartridges. If insulin glargine products were available, one was included in the data collection of the country. A summary of the insulin products surveyed (100 IU/mL unless otherwise stated) is presented in online [supplementary file 2](#SP2){ref-type="supplementary-material"}.
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One public facility (main hospital) and the closest private retail facility were selected in the capital city ('Capital') and the main urban centre in a nearby district ('District'). Private hospital data were also collected in Indonesia (Capital and District) and Hubei Province, China (Capital).

Data collection {#s2-2}
---------------

Data collection involved working back up the supply chain to identify the selling price at each stage ([table 1](#T1){ref-type="table"}) using standard forms. Data were collected first from the retailer, then the relevant wholesaler, and continued, where possible, to the port of entry for imported products, or the manufacturer for locally produced products. At each stage the key informant was informed of the purpose of the study, invited to participate and interviewed with documentary validation sought for prices. The pricing documentation could be in the form of paper or electronic invoices or price lists and depended on what was available at the facility on the day of visit as well as what the key informant was willing to share. In some cases, actual invoices of transactions were made available but this was not always the case. In addition, information about pharmaceutical policies and pricing was collected from relevant ministries and internet searches to inform interviews and triangulate findings. Where information or price data provided by key informants were not in agreement with these policies, the informants were asked to clarify and additional checks were made to validate the price data and policy information. Insulin manufacturers were also provided with a draft of the report and given an opportunity to comment on the findings and make any clarifications.

###### 

Price component 'stages' with examples

  Stage   Description        Sample price components
  ------- ------------------ --------------------------------------------------------------------------------
  1       MSP or CIF price   Manufacturer's price and freighting charges
  2       Landed cost        Banking, port clearance, inspection fees, import tariffs, importer mark-up/fee
  3       Wholesale          Overhead costs, storage charges, mark-up and local transport
  4       Retail             Overhead costs and mark-up
  5       Dispensed cost     Dispensing fee, sales tax/VAT

CIF, cost insurance freight; MSP, manufacturer\'s selling price; VAT, value-added tax.

Data collectors were experienced health professionals or academics who had participated in the previous price survey. They were trained in July 2016 and data collection took place during August to September 2016. Prices were entered into Excel workbooks with cleaning prior to analysis.

In Brazil, only one retailer and no wholesalers participated. Verified data were available down to wholesaler procurement level in all other countries except Ghana where wholesalers provided unvalidated prices only. In India (Haryana State) an unvalidated MSP was provided for one product. Where verified data were not available, MSPs and stage 1 (insurance and freight) and stage 2 (port clearance) costs were back-calculated based on publicly available information and interviews. The text refers to these back-calculated cases as 'estimated' costs or mark-ups. Local currency prices were converted to US\$ for indicative purposes (Oanda.com 13 November 2016).

Statistical analysis {#s2-3}
--------------------

The data are case studies, not a representative sample, preventing calculation of summary statistics. Therefore, only actual values and ranges are presented. Commonly surveyed products (insulin glargine and Humulin/Huminsulin) were compared across countries.

Patient and public involvement {#s2-4}
------------------------------

No patients or the general public were involved in the study.

Results {#s3}
=======

The results are presented by supply chain stage ([table 1](#T1){ref-type="table"}), the total cumulative mark-up, their contribution to the final price and comparison of similar products. Summaries of mark-up levels and the contribution of all components to the final price are shown in online [supplementary tables 1 and 2](#SP3 SP4){ref-type="supplementary-material"}, with examples in [figure 1](#F1){ref-type="fig"} and [online supplementary files 5 and 6](#SP5 SP6){ref-type="supplementary-material"}.

![Examples of the contribution of mark-ups at various stages of the supply chain to the final price of typical insulin products in the private sector in six surveys across five countries. VAT, value-added tax.](bmjgh-2019-001705f01){#F1}

Mark-ups by stage {#s3-1}
-----------------

The magnitude of mark-ups was country specific. Pricing regulations shaped both public and private sector mark-ups in China (Hubei and Shaanxi), India (Haryana) and Indonesia and, except in Indonesia, tended to keep wholesale and retail mark-ups below those seen in Ghana and Uganda, although patient selling prices were not necessarily lower. Insufficient information was available to estimate stage 1 (shipping freight and insurance) costs except in Ghana (7% public and private sectors) and Uganda (20% private sector).

In China, import port clearance (stage 2) mark-ups incurred in both public and private sectors were about 33.5% (including 5% import duty, 17% value-added tax (VAT) and 8.7% importer mark-up) (online [supplementary table 1](#SP3){ref-type="supplementary-material"}). Estimated port clearance (stage 2) components in India added around 27% but this only affected the private sector since imported insulin products were not found in public facilities. The magnitude of the port clearance mark-up was similar to Indonesia although in the latter some were inflated (100%--300%) for non-NHI system patients. Port clearance costs were much lower in Ghana (8%) and Uganda (0% public; 12% private) and generally the same for both public and private sectors. Ghana, India, Indonesia and Uganda had removed import tariffs on essential medicines including insulin, although in Ghana imported medicines still attracted an import levy (2%) and a processing fee (1%) among other charges.
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Wholesale (stage 3) mark-ups varied within (depending on product, sector and district) and between countries. In China (Hubei), wholesale (stage 3) components were about 8.7% except for imported products in the private sector (4.0%). More variability was seen in Shaanxi Province, with wholesale mark-ups ranging from 0.1% to 16.3% across public and private sectors with some remarkably low values, mostly in District facilities. No explanation for this was evident. In the Indian private sector, imported insulins in the private sector had wholesale mark-ups of 8.7% and domestically produced biosimilars attracted up to 11.1%. In Indonesia, the mark-ups varied from 15% to 20% (including public and private sectors), but were higher in Ghana (25%) and lower in Uganda (10% public, 5% private sector).

Retail (stage 4) mark-ups also varied. Hubei Province had instituted the national zero mark-up policy in the District public facilities, but Capital public facilities still added 15%--24%. The public sector mark-up was 15% in Shaanxi Province which had not yet implemented the policy. Private sector retail mark-ups ranged from 4.5% to 20.7% (including VAT) in Hubei and from 2.1% to 35.5% in Shaanxi (including VAT). Facilities with markedly lower stage 3 mark-ups in Shaanxi sometimes had larger stage 4 mark-ups, but not consistently.

Stage 5 (sales tax/VAT) add-ons were wholly represented as VAT on the retail price in the private sector. Only Uganda exempted essential medicines from sales tax. India had the lowest VAT (5% plus a 0.25% surcharge) followed by Indonesia (10%), China (17%; exempt at public or non-profit facilities), Ghana (17.5% unless exemption claimed) and Brazil (20%).

Comparisons by product characteristics {#s3-2}
--------------------------------------

Comparison of price components for imported or domestically produced insulin products was limited since only China and India had significant use of the latter. However, the only difference noted was the application of port clearance (stage 2) charges for imported products. These products had essentially the same wholesale and retail mark-ups in Hubei Province in China as imported insulins, but in Shaanxi Province there was a more varied picture but with mark-up more frequently larger for biosimilars (eg, Basalin insulin glargine cartridge 11.8% vs Lantus Solostar insulin glargine pen 5.3% wholesale mark-up in the public sector; 8.5% vs 5.7% retail in the private sector). In India the local products in the private sector attracted slightly larger wholesale (11.1% vs 8.7%) and retail (18.8% and 14.4% vs 13.1%) mark-ups.

Apart from the differential implementation of the zero mark-up policy in China (Hubei), mark-ups seldom varied systematically between Capital and District sites, and price regulations in India and Indonesia kept them similar at all sites (except two District facilities in Indonesia which levied high retail mark-ups on non-NHI patients). In Ghana, retail price components ranged from 23.9% to 56.1% (one outlier 131.2% where the pharmacy procured a particular insulin for one client) in the Capital and from 40.6% to 56.0% in the District. In Uganda, wholesale (stage 3) mark-ups were the same for both sites, but a more expensive product had a much lower retail mark-up (Actrapid vial MSP \$3.3, wholesale mark-up 5%, retail mark-up 48%, final price \$7 in both Capital and District; Mixtard 30 pen, MSP \$5.6 wholesale mark-up 5%, retail mark-up 14%, final price \$9 in District).

Public and private sectors had similar magnitudes of price components in China and Indonesia courtesy of price regulation (data from India were insufficient to compare). In Ghana, the wholesale mark-up was also the same in both sectors since they shared the same suppliers who charged the same to all clients. Public sector retail mark-ups were 43.6% (Capital) and 40.0% (District) for two products of similar MSP in the public sector and ranged from 23.9% to 56.1% (one outlier 131.2%) in the private sector in Ghana.

Analogue insulin products generally had the same or similar mark-ups as human insulins and the same was true when comparing pens or cartridges and vials. Some variation was seen in the unregulated private sector in Ghana for the 'expensive' Lantus Solostar pen (insulin glargine). The same wholesale mark-up was applied for this product as to less costly human insulins (25%) but in the District a higher retail mark-up (56%) was applied than in the Capital (24%) and this was also higher compared with human and isophane insulin products (range 33%--56%). This still resulted in a lower patient price (District \$25, Capital \$33) due to a much lower MSP (District \$11, Capital \$18), possibly due to an old procurement or procurement outside of usual supply chains.

Cumulative mark-ups {#s3-3}
-------------------

Across the surveys, cumulative marks-ups ranged from 8.7% to 47.7% for locally produced and from 10.0% to 565.8% for imported insulins (online [supplementary table 1](#SP3){ref-type="supplementary-material"}). This varied between countries with a complex picture in China. Public and private sectors are discussed together and were usually higher in the private sector.

In China (Hubei), public sector cumulative mark-ups ranged from 45% to 80% and were lower in the District than the Capital, for example, Humalog (lispro) cartridge costs US\$10.90 in the District public and private sectors (45.2% cumulative mark-up) but US\$11.62 (54.8%) in the Capital private sector and US\$12.54 (67%) in the Capital public sector. The cumulative mark-up was much lower for locally produced regular porcine insulin (9%--25%) with no port clearance (stage 2) costs and reduced VAT. However, in Shaanxi Province, locally produced insulin cumulative mark-ups ranged from 27% to 29% in the public and from 10% to 36% in the private sector. Public sector total mark-ups were higher than the private sector in the Capital, but the opposite was true in the District (except for insulin glargine).

In Ghana, the cumulative mark-up was around 100% in public and private sectors, with more variation in the private sector (range 92%--126%, one outlier 224%), whereas in India (Haryana) imported products accrued around 65% but local products had cumulative mark-ups of 38%--48%. In Indonesia, for NHI patients, the cumulative mark-up was in the range of 98%--111%, but 98%--566% for non-NHI patients. In Uganda private sector cumulative mark-ups were 110% (Actrapid vial) and 61% (Mixtard prefilled pen).

Contribution to final price {#s3-4}
---------------------------

The proportion of the final selling price attributed to the MSP varied from 15% to 92% (usually around 45%--70%), being higher for locally manufactured products. In Hubei, China, the MSP comprised 56%--92% of the final price, being largest for locally produced products that were only found in the public sector (online [supplementary table 2](#SP4){ref-type="supplementary-material"}; [figure 1](#F1){ref-type="fig"}). The MSP contributed more in the District courtesy of the public sector zero mark-up policy. Similarly, in Shaanxi Province, the MSP contributed 56%--70% of the final price of imported products, slightly more in the private than the public sector, and was higher for local biosimilar products---around 78% in the public and 73%--91% in the private sector. Stage 2 costs made up about 20% of the final price of imported products in both provinces, and retail mark-ups about 13% in the public sector (varying between 2% and 26% in the private sector, with variation by region and origin of the product).
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In Ghana, the MSP, wholesale (stage 3) and retail (stage 4) mark-ups contributed about half, 14% and 30%, respectively, to public sector patient prices with a similar picture in the private sector. The MSP contribution was similar in Indonesia (50%) except where large importer or retailer mark-ups were present (range 15%--31%). In Haryana, the MSP was 68%--72% of the final price for local biosimilars in both public and private sectors (see online [supplementary table 2](#SP4){ref-type="supplementary-material"}). For originator products, it was around 61% with port clearance (stage 2) costs 16.7% of the price for imports. In the Uganda private sector, the MSP was 48% of the final price for Actrapid (regular) vial with retail mark-up comprising 32%. For Mixtard (isophane/regular mix) prefilled pen, the MSP contributed 62% and the retail mark-up 12%.

Comparison of Humulin and Huminsulin products {#s3-5}
---------------------------------------------

Humulin/Huminsulin products (Eli Lilly) in Ghana, India (Haryana) and Indonesia across a variety of presentations and insulin mixes ([table 2](#T2){ref-type="table"}) showed national variations in the magnitude of mark-ups. Cumulative mark-ups varied from about 65% (Haryana) to 110% (Ghana) and from 260% to 565% in Indonesia (including non-NHI patients). The MSP was 47% of the final price in Ghana, 60% in Haryana and 15%--28% in Indonesia where port clearance (stage 2) costs predominated due to high importer mark-ups ([figure 2](#F2){ref-type="fig"}).

![Contribution of mark-ups to final price for Humulin/Huminsulin products in three countries. VAT, value-added tax.](bmjgh-2019-001705f02){#F2}

###### 

Comparison of mark-ups for Humulin/Huminsulin human insulin products in three countries

  Product                              Ghana                            India (Haryana State)            Indonesia                                                                           
  ------------------------------------ -------------------------------- -------------------------------- -------------------------------- -------------------------------- ----------------- -----------------
  **Insulin type**                     Insulin, lente zinc suspension   Isophane/regular insulin 70/30   Isophane/regular insulin 70/30   Isophane/regular insulin 70/30   Regular insulin   Regular insulin
  Volume (mL)                          10                               10                               3                                10                               3                 3
  Strength (IU/mL)                     100                              100                              100                              40                               100               100 
  Sector                               Public                           Private                          Private                          Private                          Public            Private
  Import                               Import                           Import                           Import                           Import                           Import            Import
  Region                               Capital                          District                         District 1                       District 2                       Capital           Capital
  MSP (US\$)                           5.1                              7.0                              2.2                              1.3                              11.2              11.2
  Stage 1 (%)                          7.0                              7.0                              0.0                              0.0                              0.0               0.0
  Stage 2 (%)                          8.0                              8.0                              27.6                             26.5                             121.3             303.0
  Stage 3 (%)                          25.0                             25.0                             8.7                              8.7                              20.0              18.0
  Stage 4 (%)                          43.6                             50.0                             13.1                             13.1                             26.0              30.0
  Stage 5 (%)                          0.0                              0.00                             5.3                              5.3                              7.9               7.7
  Cumulative total (%)                 107.5                            116.7                            65.1                             63.7                             261.2             565.8
  Final price (US\$)                   10.6                             15.2                             3.6                              2.1                              40.3              74.6
  Standardised price to 10 mL 100 IU   10.6                             15.2                             12.0                             5.3                              134.3             248.7

Stage 1: insurance and freight. Stage 2: clearance charges. Stage 3: wholesale mark-ups. Stage 4: retail mark-ups. Stage 5: sales tax/value-added tax (VAT).

MSP, manufacturer\'s selling price.

Comparison of insulin glargine products {#s3-6}
---------------------------------------

Four countries (five surveys) surveyed insulin glargine ([table 3](#T3){ref-type="table"}). Stage 2 (port clearance) charges added substantially to imported products, but distribution and retail mark-ups varied both between and within countries or regions with no common pattern.

###### 

Comparison of insulin glargine mark-ups between countries

  --------------------------------------------------------------------------------------------------------------------------------------
                         China\    China\      Ghana      India (Haryana)   Indonesia   China (Shaanxi)                       
                         (Hubei)   (Shaanxi)                                                                                  
  ---------------------- --------- ----------- ---------- ----------------- ----------- ----------------- --------- --------- ----------
  Import                 Import    Import      Import     Import            Import      Import            Import    Local     Local

  Region                 Capital   Capital     District   Capital           District    Capital           Capital   Capital   District

  Sector                 Public    Public      Private    Private           Private     Public            Private   Public    Private

  MSP (US\$)             20.7      21.4        10.8       18.4              4.9         22.1              22.1      20.2      20.2

  Stage 1 (%)            0.0       0.0         7.0        7.0               0.0         0.0               0.0       0.0       0.0

  Stage 2 (%)            33.5      33.5        8.0        8.0               27.6        26.8              182.0     0.0       0.0

  Stage 3 (%)            8.7       5.3         25.0       25.0              8.7         15.0              15.0      11.8      0.5

  Stage 4 (%)            15.0      15.0        56.0       23.9              13.1        26.0              15.0      15.0      9.3

  Stage 5 (%)            0.0       0.0\*       0.0        0.0               5.3         7.9               8.7       0.0       0.0\*

  Cumulative total (%)   66.9      61.6        125.4      79.0              65.1        98.3              305.4     28.6      9.8

  Final price (US\$)     34.5      34.5        24.7       32.7              8.0         43.8              89.5      26.0      22.2
  --------------------------------------------------------------------------------------------------------------------------------------

In some cases more than one glargine product was surveyed, but only a single representative product is shown unless major differences were evident. Note that some products are complete pens and others are cartridges.

Stage 1: insurance and freight. Stage 2: clearance charges. Stage 3: wholesale mark-ups. Stage 4: retail mark-ups. Stage 5: sales tax/value-added tax (VAT).

\*VAT incorporated in stage 4.

MSP, manufacturer\'s selling price.

Other information {#s3-7}
-----------------

Information supplied from key informant interviews indicated that discounts and trade schemes are used in the supply chain either from manufacturers or wholesalers. In Ghana, discounts (up to 20%) offered by wholesalers to retailers depended on the quantities and payment terms, while in India invoices showed cash discounts on total invoice values (three cases; range 1%--8%) and one deal (10% free) with the benefits not passed on to insulin users.

Discussion {#s4}
==========

This is the first paper to examine price components of insulin products across countries. While there are individual insights for each country, and limited data on price components from the Chinese surveys have been published as part of wider studies,[@R10] there were no systematic patterns in mark-ups when comparing manufacturers, sectors, regions, import or locally manufactured, type, or presentation of insulin.

Mark-ups were similar for locally manufactured insulins and imports. The MSP contributed a greater proportion of the final price of locally produced insulins due to the absence or reduction of stage 2 (port clearance) costs. Most of these examples came from India (Haryana) where private sector price regulation maintained similar wholesale and retail mark-ups for both local and imported products. In the private sector in China (Shaanxi), local products often had higher mark-ups than imported products showing that such mark-ups do not necessarily reflect actual costs. Indeed, lower cost items may need higher mark-ups to be sufficiently profitable.[@R8]

Both competition and price regulation can address MSPs (which constituted the bulk of many prices) as well as mark-ups.[@R12] While price regulation may play a role, it can be difficult to enforce in LMICs and may have unexpected detrimental effects if implemented inappropriately.[@R7] Indonesia has price regulation with set e-procurement prices, wholesale and retail margins in both public and private settings for NHI patients. At some facilities, non-NHI patients were paying almost double for insulin due to 'unreasonable' mark-ups (150%--200%) at the importer or retailer level. Until NHI coverage is universal, non-NHI patients need greater protection. Further investigation is required to explore the observation that price regulation did not necessarily result in lower patient prices, which could reflect low competition or poor procurement practices. Price monitoring and regular evaluation should support any pricing regulations.

The difficulty of enforcing price regulations was underlined by the slow implementation of the 2012 'zero mark-up policy' in the public sector in China which had only been implemented at the District sites in Hubei Province. Medicines are a major source of income for public health facilities in China[@R11] and this may be the reason behind the slow implementation of the policy. This is complicated by fragmentation of policy implementation in public health facilities.[@R11] The observation in China that prices for human and analogue insulins were somewhat similar and relatively high with mark-ups 'adjusted' to make up the differences may be a result of perverse incentives in regulations. A pricing regulation strategy incorporating international referencing could help address this.[@R13]

The results for India were similar to those reported by Sharma and Kaplan[@R16] which is a reflection of the price regulations in place for distribution and retail mark-ups. However, there was a difference in the estimated port clearance (stage 2) costs. In this survey, these were estimated at about 20% based on a single unverified MSP provided by a key informant and applied the same across all products. Sharma and Kaplan reported import to wholesale price mark-ups usually of the order of 11%--26% (with some as low as 5% and one outlier of 75%).

There were seldom any differences in the mark-ups between District and Capital regions apart from a few country-specific findings, in contrast to previous work in Kyrgyzstan that showed wholesalers charging more for distant facilities.[@R17] In the China (Shaanxi) public sector, Capital wholesale mark-ups pushed up total mark-ups particularly for locally manufactured products. Otherwise, wholesalers often charged the same percentage mark-up regardless of price in both public and private sectors. In Ghana's private sector, District retailers tended to have higher mark-ups which may reflect higher risk in carrying insulin stock. In general, retailer mark-ups varied considerably where the absence of regulations allowed. Dispensing fees were not used in any of the countries.

China and India did not have mark-up policies that favoured locally produced insulins. However, these products tended to be lower cost due to the absence of stage 2 costs. It was difficult to compare public and private sector pricing strategies since insulin was provided free of charge to patients in the public sector in most of the countries---although it was not necessarily available,[@R10] a common issue with public sector medicines in general.[@R18] The MSP tended to contribute less to products procured by public tender in Ghana and Uganda, but these were products different from those available at private retailers. Private sector had greater variation in wholesale and retail mark-ups due to less regulation. The public sector wholesale (stage 3) mark-up in Ghana was 25% while in Uganda the National Medical Stores charged a flat 10% to cover port clearance (stage 2) and wholesale costs. Such charges vary widely between LMICs and within regions,[@R7] and there is scope for reduction of public sector wholesaling charges as a means to reducing prices to insulin users.

Most studies were unable to identify the various port clearance (stage 2) charges. However, in Ghana, while insulin products were exempt from import duties (as in India, Indonesia, Uganda), they attracted 3.5% other charges including a 'special import levy', and other levies to support regional bodies, export development, and processing, in addition to port clearing and bank charges. Such 'hidden' charges have been identified in other countries on medicine imports, such as levies for the Standards Association and Ministry of Defence in Sudan.[@R9] These can have a substantial effect on prices since they are incurred at an early stage of the supply chain.

In addition, all countries apart from Uganda charged some form of tax on sales of insulin, with mechanisms for VAT recovery by wholesalers in Ghana and Indonesia reportedly not used due to cumbersome procedures, and with no system to monitor if reduced costs from such exemption were passed on to insulin users. Reduced or eliminated taxes on insulin could result in lower prices in the private sector where many patients source their medicines due to poor availability in the public sector.[@R13]

Across the studies it was clear that there was a lack of transparency about prices, particularly the MSP but also at wholesale level. Discounts, rebates and other trade practices add to the confusion of pricing along the supply chain, benefiting suppliers without evidence of benefit to patients, something that has been addressed in South Africa by outlawing such deals.[@R19] While recognising concerns about confidentiality of business practices, this also means that it is not possible for insulin users, government or insurers to know whether they are being charged a 'fair' price, especially in markets (such as the insulin market) where competition is limited.[@R4]

While these data only provide a snapshot of insulin price components in the various countries, the lack of systematic differences between price components of imported/domestically produced insulins, human/analogue insulins and those sold in the capital compared with the district suggests that insulin products are generally supplied and priced in a manner similar to other medicines. An exception would be where insulin is exempted from import duty in Ghana (also no import duty in Uganda as an essential medicine). Studies of wholesale and retail mark-ups in pharmaceutical supply chains in LMICs are limited and have not shown any consistency, although flat percentage mark-ups tend to predominate in the public sector[@R8] and probably also the private sector as shown by case studies in Ghana and Malawi[@R20] and supported by this study. Only a few LMICs, such as Mali, have either regulated mark-ups or made exemptions from mark-ups or taxes for certain essential medicines, which may include insulin.[@R8] Mark-ups do not seem to vary by disease class, but rather mark-ups and prices are set in order to achieve an overall profitability for each of the players in the supply chain, at least in the private sector, taking into account international, national and local factors such as national pharmaceutical policy, supply chain constraints, business environment, market share, competition and demand, as has been described for antimalarial artemisinin combination therapies.[@R22] This may mean that it may be difficult to promote 'insulin only' solutions in the private sector to improve access unless they are simple to implement in the local environment and make economic sense to supply chain actors.

Limitations of the data {#s4-1}
-----------------------

Lack of information from manufacturers, importers and wholesalers meant that MSPs and port clearance (stage 2) costs were estimated based on interviews and publicly available information. Stage 2 costs were applied uniformly whereas they might vary depending on consignment value and other factors, meaning MSPs may show wider variability. Despite this, the use of verified field data allows for general impressions, trends and characteristics to be assessed in these six countries. The case study method is better suited for use by individual countries to examine their own situation and devise policy interventions. Only gross international trends would likely be observed between countries. International comparisons are also difficult due to the different insulin products surveyed in each country. However, this reflected the reality of use in the countries, and insulin glargine products were surveyed where available in order to facilitate international comparison.

Conclusions {#s5}
===========

The country case studies indicate no clear patterns in insulin price components, suggesting there is no one-size-fits-all approach. However, various country-specific issues needing intervention were identified. The removal of tariffs and taxes can help lower prices. Competitive public procurement can target high MSPs, but suppliers are limited. Price regulation (including regressive mark-up strategies) can address MSPs as well as mark-ups and may play a role, but needs to be supported with price monitoring, market surveillance and enforcement. Even so, opacity on true manufacturing costs can undermine such regulation. Transparency of insulin prices throughout the supply chain is needed but remains a challenge in countries.
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